quinazolines has been researched along with Weight Reduction in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad, H; Dogra, S; Dwivedi, AK; Jaiswal, S; Kumar, A; Lal, J; Pasam, VR; Rashid, M; Shukla, M; Siddiqi, MI; Singh, K; Singh, M; Singh, SK; Sona, C; Thakur, RK; Tripathi, RP; Umrao, D; Wahajuddin, M; Yadav, A; Yadav, PN | 1 |
| Tibaldi, JM | 1 |
| Hansen, G; Hansen, HH; Jelsing, J; Klein, T; Mark, M; Paulsen, S; Vrang, N | 1 |
| Broedl, UC; DeFronzo, RA; Kaste, R; Lewin, A; Liu, D; Patel, S; Woerle, HJ | 1 |
| Schmidt, C | 1 |
| Arimura-Omori, M; Hamada, N; Harada, E; Ikeda-Harada, C; Mikumo, H; Nakanishi, Y; Ogata-Suetsugu, S; Suzuki, K; Yanagihara, T; Yokoyama, T | 1 |
| Casper, MD; Chaki, S; Choi, J; Grottick, AJ; Han, S; Hauser, EK; Hsu, D; Kanuma, K; Kramer, B; Morgan, M; Sekiguchi, Y; Semple, G; Sengupta, D; Thomsen, W; Tran, TA; Vallar, P; Whelan, K; Zou, N | 1 |
| Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Mlak, R; Wojas-Krawczyk, K | 1 |
| Elrod, S; Harrington, C; McLaughlin-Middlekauff, J; Singh-Franco, D | 1 |
| Brink, C; Carter, CA; Chen, C; Gilbert, KS; Maxuitenko, YY; Vincent, P; Waud, WR; Zhang, X | 1 |
| Aherne, GW; Benstead, J; Clarke, SJ; Farrugia, DC; Jackman, AL; Pritchard, DM | 1 |
1 review(s) available for quinazolines and Weight Reduction
| Article | Year |
|---|---|
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss | 2014 |
1 trial(s) available for quinazolines and Weight Reduction
| Article | Year |
|---|---|
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome; Weight Loss | 2015 |
9 other study(ies) available for quinazolines and Weight Reduction
| Article | Year |
|---|---|
Novel Tetrahydroquinazolinamines as Selective Histamine 3 Receptor Antagonists for the Treatment of Obesity.
Topics: Animals; Anti-Obesity Agents; Blood Glucose; Diet, High-Fat; HEK293 Cells; Histamine H3 Antagonists; Humans; Male; Mice, Inbred C57BL; Molecular Structure; Obesity; Proto-Oncogene Proteins c-fos; Quinazolines; Receptors, Histamine H3; Stereoisomerism; Structure-Activity Relationship; Weight Loss | 2019 |
The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat.
Topics: Animals; Appetite Depressants; Body Weight; Diet, High-Fat; Dietary Sucrose; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Drug Therapy, Combination; Glucagon-Like Peptide 1; Linagliptin; Male; Obesity; Purines; Quinazolines; Rats; Rats, Sprague-Dawley; Weight Loss | 2014 |
Cediranib aims for a comeback.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Female; Humans; Myelodysplastic Syndromes; National Cancer Institute (U.S.); Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Protein-Tyrosine Kinases; Quinazolines; United Kingdom; United States; Uterine Cervical Neoplasms; Vaginal Fistula; Vascular Endothelial Growth Factor A; Weight Loss | 2015 |
Neutrophil elastase inhibitor sivelestat ameliorates gefitinib-naphthalene-induced acute pneumonitis in mice.
Topics: Acute Disease; Animals; Bronchoalveolar Lavage Fluid; Female; Gefitinib; Glycine; Humans; Kaplan-Meier Estimate; Leukocyte Count; Leukocyte Elastase; Lung; Mice, Inbred C57BL; Naphthalenes; Neutrophils; Pneumonia; Quinazolines; Serine Proteinase Inhibitors; Sulfonamides; Weight Loss | 2017 |
Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.
Topics: Administration, Oral; Animals; Anti-Obesity Agents; Cyclohexylamines; Eating; Humans; Male; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Somatostatin; Structure-Activity Relationship; Weight Loss | 2009 |
The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Karnofsky Performance Status; Lipoproteins, HDL; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Sex Factors; Survival Analysis; Time Factors; Weight Loss | 2011 |
Response letter. Effects of linagliptin.
Topics: Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Postprandial Period; Purines; Quinazolines; Respiratory System; Weight Gain; Weight Loss | 2012 |
Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytotoxins; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Vinblastine; Vinorelbine; Weight Loss; Xenograft Model Antitumor Assays | 2007 |
Balb/c mice as a preclinical model for raltitrexed-induced gastrointestinal toxicity.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxyuridine; Diarrhea; Digestive System; Dose-Response Relationship, Drug; Folic Acid; Intestinal Mucosa; Intestine, Large; Intestine, Small; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Quinazolines; Thiophenes; Thymidine; Thymidylate Synthase; Weight Loss | 2000 |